Elotuzumab |
| رقم الكتالوجGC64565 |
Elotuzumab هو جسم مضاد أحادي النسيلة موجه ضد مستقبلات SLAMF7لا يحتوي Elotuzumab على نشاط هام مضاد للورم النخاعي عند إعطائه كعامل واحد مع المايلوما المتعددة المنكسرة أو المقاومة للحرارة (RRMM)يؤدي Elotuzumab إلى تحسين الاستجابة والنتائج عند الدمج مع عوامل أخرى مضادة للورم النخاعي
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 915296-00-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents[1].
[1]. Magen H, et al. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187-195.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *